

Product Description

Pioneering GTPase and Oncogene Product Development since 2010

HUMAN CXCL7 (C-6HIS) PROTEIN

目录: 12056

产品名称: Human CXCL7 (C-6His) Protein

规格: 10 μg, 50 μg and 100 μg

基因符号: Platelet Basic Protein;PBP;C-X-C Motif Chemokine

7;Leukocyte-Derived Growth Factor;LDGF;Macrophage-Derived Growth

Factor;MDGFSmall-Inducible Cytokine B7;PPBP;CTAP3;CXCL7;SCYB7;TGB1;THBGB1

Target: CXCL7

UNIPROT ID: P02775

描述: Recombinant Human C-X-C Motif Chemokine 7 is produced by our Mammalian expression system and the target gene encoding Ser35-Asp128 is expressed with a 6His tag at the C-terminus.

背景: Human Chemokine (C-X-C motif) Ligand 7 (CXCL7), also known as neutrophil activating peptide 2 (NAP-2), is a member of the CXC chemokines containing an ELR domain (Glu-Leu-Arg tripeptide motif). Similar to other ELR domain containing CXC chemokines, such as IL-8 and the GRO proteins, CXCL7 binds CXCR2, chemoattracts and activates neutrophils. CXCL7, Connective Tissue Activating Protein III (CTAPIII) and β thrombogulin (β TG), are proteolytically processed carboxylterminal fragments of platelet basic protein (PBP) which is found in the alphagranules of human platelets. Although CTAPIII, β TG, and PBP represent amino-terminal extended variants of NAP2 and possess the same CXC chemokine domains, these proteins do not exhibit CXCL7/NAP2 activity. CXCL7 induces cell migration through the G-protein-linked receptor CXCR-2.

Species/Host: HEK293
Molecular Weight: 11.3 KDa

Molecular Characterization: Not available

纯化:: Greater than 95% as determined by reducing SDS-PAGE.

Formulation & Reconstitution: Lyophilized from nanodisc solubilization buffer (20 mM Tris-HCl, 150 mM NaCl, pH 8.0). Normally 5% – 8% trehalose is added as protectants before lyophilization.

储存和运输: Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.



Product Description

Pioneering GTPase and Oncogene Product Development since 2010




Figure 1. Greater than 95% as determined by reducing SDS-PAGE.